SCHEMBL7501233

SCHEMBL7501233

N=c1sccn1Cc1ccc(F)nc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 7/20 0.69
CHRNA4 P43681 7/20 0.69
CHRNA1 P02708 1/20 0.69
CHRNA7 P36544 1/20 0.69
KMT2A Q03164 1/20 0.49
CYP11B1 P15538 1/20 0.47
CYP11B2 P19099 1/20 0.47
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
RAD52 P43351 1/20 0.35
CYP2E1 P05181 1/20 0.35
CYP2A6 P11509 1/20 0.35
CYP2B6 P20813 1/20 0.35
GRIN1 Q05586 1/20 0.34
GRIN2B Q13224 1/20 0.34
DRD2 P14416 1/20 0.34
DRD4 P21917 1/20 0.34
DRD3 P35462 1/20 0.34
LMNA P02545 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7495819 0.82 CHRNB2 (0.69) CHRNB2CHRNA4CHRNA1CHRNA7KMT2A
SCHEMBL7504331 0.82 CHRNB2 (1.00) CHRNB2CHRNA4CHRNA1CHRNA7KMT2A
SCHEMBL7504394 0.74 CHRNB2 (0.58) CHRNB2CHRNA4CHRNA1CHRNA7KMT2A
SCHEMBL7501821 0.74 CHRNB2 (0.67) CHRNB2CHRNA4CHRNA1CHRNA7KMT2A
SCHEMBL7506033 0.72 CHRNB2 (0.60) CHRNB2CHRNA4CHRNA1CHRNA7KMT2A
SCHEMBL23749741 0.72 CHRNB2 (0.59) CHRNB2CHRNA4CHRNA1CHRNA7KMT2A
SCHEMBL7503621 0.71 CYP11B1 (0.41) CHRNB2CHRNA4CHRNA1CHRNA7KMT2A
SCHEMBL7498533 0.69 CHRNB2 (0.60) CHRNB2CHRNA4CHRNA1CHRNA7KMT2A
SCHEMBL7506101 0.69 CHRNB2 (0.56) CHRNB2CHRNA4CHRNA1CHRNA7KMT2A
SCHEMBL1273680 0.68

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020028809-A1 Heterocyclic compounds having effect of activating a4beta2 nicotinic acetylcholine receptors SUNTORY LIMITED 2002-03-07 US disclosed
EP-1176141-A1 HETEROCYCLIC COMPOUNDS HAVING EFFECT OF ACTIVATING NICOTINIC ACETYLCHOLINE $g(a)4$g(b)2 RECEPTOR SUNTORY LIMITED (JP) 2002-01-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020028809-A1 Heterocyclic compounds having effect of activating a4beta2 nicotinic acetylcholine receptors CHRNA2, CHRNA7, CHRNB2 CHRNB2 3/4885CHRNA4 8/4885CHRNA1 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.